CelLBxHealth plc (LON:CLBX)
2.15p+24.64%
Spriggl Score: Weak— see the number + sub-scores with a free Spriggl account
Last 30 trading days
Spriggl AI Verdict
“AstraZeneca deal signals genuine clinical utility; cash runs short unless orders materialise soon.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About CelLBxHealth plc
CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTC…
- Sector:
- Healthcare
- Industry:
- Diagnostics & Research
- Market Cap:
- £35.0M
Recent dividends
No recent dividends recorded.
Get the full Spriggl analysis — free
Sign up for a free Spriggl account to unlock the full Spriggl Score breakdown, screener, watchlist, and AI investment analysis on CelLBxHealth plc and 1,600+ UK and US stocks.
Start free